亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Antisense Oligonucleotide Therapy for B Cell Mediated Cancers

技术优势: Targets leukemia cells Conjugated for antisense oligonucleotide Targets precursor B cells Monoclonal antibody

详细技术说明: Antisense compounds have been used to modulate protein expression by binding to a target mRNA encoding the protein. Application of oligonucleotide-based technologies in cancer is promising but has had limited success in vivo due to the ineffective cell-targeting. Better targeting is needed to improve therapeutic efficacy of oligonucleotide-based cancer therapies in vivo. Researchers at the University of California, Davis have developed a precursor B cell (pre-B) acute lymphoblastic leukemia (ALL) cell targeting compound by directly conjugating an antisense oligonucleotide with an anti-CD22 antibody. This method specifically targets a transcription factor identified to be involved in pre-B ALL cell survival. In-vivo therapeutic efficacy has been successfully tested in pre-B ALL xenograft mouse models and Reh cell line, as well as patient-derived leukemia cells. Utilizing this method also provides new opportunities to treat and target B cells associated with leukemia, lymphoma and autoimmune disorders.

*Abstract: Researchers at the University of California, Davis have developed a targeted therapy using an antisense oligonucleotide (ASO) to treat precursor B cell (pre-B) acute lymphoblastic leukemia (ALL).

*Principal Investigation: Name: Nitin Nitin
Department:

Name: Noriko Satake
Department:

Name: Joseph Tuscano
Department:

Name: Shuling Guo
Department:

Name: Michael Oestergaard
Department:

Name: Punit Seth
Department:

其他

Additional Technologies by these Inventors

Tech ID/UC Case

29215/2014-686-0

Related Cases

2014-686-0

欲了解更多信息，请点击这里